Key takeaways
Questions this review answers
Hydroxyapatite is the calcium phosphate mineral that makes up most of tooth enamel. Toothpastes add a synthetic particle form of it, usually at 10%. We searched for human studies of hydroxyapatite oral care products published through July 2026 and kept 14 sources: six randomized controlled trials, one in-situ study, two systematic reviews with meta-analyses, and five papers we use for context on mechanism, methods, and guidelines. Laboratory studies on extracted teeth appear only as context — they show what an ingredient can do to a tooth surface, not what happens in a mouth over a year.
The most useful evidence compares hydroxyapatite directly against fluoride, the best-tested ingredient in oral care. Three randomized trials have done this, in three different groups of people.
In an 18-month double-blind trial, 189 adults brushed with either a 10% hydroxyapatite toothpaste or a 1450 ppm fluoride toothpaste. 89.3% of the hydroxyapatite group developed no new decayed surfaces, against 87.4% with fluoride — the hydroxyapatite paste was statistically no worse.
In a one-year trial of 207 young children, new early caries lesions appeared in 72.7% of the hydroxyapatite group and 74.2% of the fluoride group — again, no meaningful difference.
A third trial found the same pattern in orthodontic patients — a group whose brackets make cleaning hard and caries risk high. One thing to read carefully: all three were non-inferiority trials. They were designed to test "no worse than fluoride," not "better than fluoride." That's the honest claim the data supports, and it's the only one we'll make. A 2025 triple-blind trial in 610 children also suggests hydroxyapatite may add something when combined with fluoride in one paste — an early signal worth watching, not yet a settled finding.
Teeth lose and regain mineral all day. Acid from plaque bacteria pulls calcium and phosphate out of enamel; saliva puts some back. A caries lesion starts when losses outpace gains — first as a chalky white patch with the surface still intact. At that early stage the process can slow, stop, or partly reverse. Once the surface breaks and a cavity forms, it cannot grow back; that's dental work, and it's why check-ups matter — early lesions are found in a dental chair, not a bathroom mirror.
In an in-situ study, 30 adults wore enamel samples with artificial early lesions while brushing with 10% hydroxyapatite or 500 ppm fluoride paste for 14 days per arm. Both remineralized the lesions and inhibited new demineralization.
So the plain-language claim the evidence supports is: hydroxyapatite toothpaste helps the remineralization side of the balance for early-stage lesions, about as well as fluoride did in the same studies. It is not a repair kit for cavities, and no toothpaste is.
Sensitivity happens when the channels in exposed dentin carry cold and pressure straight to the nerve. Hydroxyapatite particles can plug those channels, and here the clinical record is broader than for caries.
A 2023 meta-analysis pooling 8 randomized trials found hydroxyapatite products reduced sensitivity about 40% more than placebo, and modestly outperformed fluoride-based comparators (~23%).
An 8-week four-arm trial found 10–15% nano-hydroxyapatite pastes as effective as a leading desensitizing ingredient (calcium sodium phosphosilicate). Keep one number in mind, though: in sensitivity research the placebo response is famously large — a network meta-analysis across desensitizing pastes found most actives separated from placebo by less than they separated from nothing. Expect modest, real relief — not a switch flipping off. Sensitivity that's new, one-sided, or worsening is a see-your-dentist symptom, not a toothpaste problem.
The caries trials used 10% hydroxyapatite (microcrystalline in the children's trial), brushing two to three times daily, for 6 to 18 months. Sensitivity trials used 10–15%, twice daily, with relief typically measured from 2 to 8 weeks. These are amounts used in published studies, not recommendations — many products on shelves contain far less than the studied concentrations, which is worth checking before you buy. The full table is on the hydroxyapatite reference page.
Four things keep this evidence from being the last word. First, funding: the three head-to-head trials share authors employed by a hydroxyapatite toothpaste manufacturer, a pattern that historically inflates effect sizes — independent replication hasn't happened yet. Second, the non-inferiority margins were generous; "no worse" was defined loosely enough that a modest real difference could hide inside it. Third, scale: fluoride's caries evidence spans 96 studies and tens of thousands of participants in the Cochrane review; hydroxyapatite's spans three trials. Fourth, regulation: in the US, only fluoride compounds may carry a cavity-prevention claim, so hydroxyapatite pastes are sold as cosmetics — Japan, which has used hydroxyapatite since 1980, approved it as an anti-caries active in 1993. Different regulators, reading different files, at different times.
If you want the most-tested ingredient, fluoride is still it. If you want or need a fluoride-free paste — young children who swallow toothpaste, or personal preference — 10% hydroxyapatite is the best-studied alternative, with three randomized trials showing it kept pace with fluoride and consistent evidence for sensitivity relief. Whichever you choose: brushing twice a day matters more than which active is in the tube, and neither replaces regular dental visits. If new independent trials change this picture, this page will change with it.
Update history
Aug 2026 — Added the 2025 hydroxyapatite-plus-fluoride children's trial; expanded the limitations section.
Mar 2026 — First published.
We summarize published studies in plain language. We can't see your teeth — your dentist can, and early problems are found in an exam chair, not an article. Keep your regular visits, and bring questions like these to them.
Product sales fund the research — we have no sponsors. The review team works independently of the shop: findings publish whether or not they flatter what we sell, and this page's limitations section is the proof.